Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AZD7762 |
Trade Name | |
Synonyms | AZD-7762 |
Drug Descriptions |
AZD7762 is an ATP-competitive CHK1/CHK2 inhibitor, which abrogates DNA damage-induced cell cycle checkpoints, and demonstrates antitumor activity when administered in combination with DNA-damaging agents (PMID: 18790776, PMID: 32335582, PMID: 31372095). |
DrugClasses | CHK Inhibitor (Pan) 2 |
CAS Registry Number | 860352-01-8 |
NCIT ID | C66961 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AZD7762 | AZD7762 | 2 | 0 |
AZD7762 + Berzosertib | AZD7762 Berzosertib | 0 | 0 |
AZD7762 + Cisplatin | AZD7762 Cisplatin | 1 | 0 |
AZD7762 + Gemcitabine | AZD7762 Gemcitabine | 0 | 0 |
AZD7762 + Hydroxyurea + VE-821 | AZD7762 Hydroxyurea VE-821 | 0 | 0 |
AZD7762 + Irinotecan | AZD7762 Irinotecan | 0 | 0 |
AZD7762 + Ixazomib | AZD7762 Ixazomib | 0 | 0 |
AZD7762 + VE-821 | AZD7762 VE-821 | 0 | 0 |